The Biggest Pharma Stock Blowups Of 2016

Novavax, Inc. NVAX’s massive 84.5 percent Friday blowup was certainly a shock for biotech investors. However, in an industry where a company’s fate can lie primarily in a single drug candidate, blowups like Novavax’s happen all too frequently. Here’s a look at five of the biggest one-day biotech blow-ups of 2016.

Mirati Therapeutics, Inc. MRTX: -44 percent

Back in June, Mirati reported results of a Phase 1b study of its non-small cell lung cancer leading drug candidate, glesatinib. The market sure didn’t like the excessive amount of side effects, and the stock plunged.

Chiasma Inc CHMA: -63 percent

Chiasma shareholders suffered a similar fate back in April when the FDA rejected the company’s experimental pituitary gland growth disorder drug.

Related Link: The Search For Silver Linings In The Cloud Of Negative Novavax News

ProNAi Therapeutics Inc DNAI: -68 percent

ProNAi stock plummeted 68 percent in a single day back in June when the biotech company reported that it was suspending development of its leading cancer drug in light of poor trial results.

Infinity Pharmaceuticals Inc. INFI: -69 percent

Sometimes drug trial results can prove disastrous even when a company hits its target. In June, Infinity announced that its non-Hodgkin lymphoma treatment hit its primary response rate target. Unfortunately, partner AbbVie Inc ABBV was not impressed with the results and decided to pull its funding.

Novavax: -84 percent

Novavax shares plummeted Friday when the company reported that its Phase III trial of its RSV F-protein recombinant nanoparticle vaccine failed to replicate its Phase II success. Now the company and the stock are back to square one.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsEducationHealth CareTop StoriesMoversGeneralglesatinibRSV vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!